Webcast
Top 10 Questions Community Oncologists Ask About CELMoDs For MM
Suggested Readings
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.
Thakurta A, et al. Oncotarget. 2021;12(15):1555-1563.
Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM.
Alvaro ME, et al. Eur J Haematol. 2026. doi: 10.1111/ejh.70134. Epub ahead of print.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lonial S, et al. Lancet Haematol. 2022;9(11):e822-e832.
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.
Lonial S, et al. Future Oncol. 2025;21(14):1761-1769.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG, et al. N Engl J Med. 2023;389(11):1009-1022.
Diagnosis and management of multiple myeloma: a review.
Cowan AJ, et al. JAMA. 2022;327(5):464-477.
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107.
Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group.
Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.
Linked Resources
GUIDELINES
Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology.
CLINICIAN RESOURCES
International Myeloma Working Group
Multiple Myeloma Research Foundation
PATIENT EDUCATION RESOURCES
Patient Advocacy Group Education Resources
Cancer Support Community
Blood & Marrow Transplant Information Network
Blood Cancer United
Related activities
Webcast
0.75 CME
Top 10 Questions Community Oncologists Ask About CELMoDs For MM
A Top 10 Activity
| Faculty: | Joseph Mikhael, MD, MEd, FRCPC, FACP |
| Release: | 04/30/2026 |
| Expiration: | 04/30/2027 |
